These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11449262)

  • 1. Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats.
    Perutz MF; Windle AH
    Nature; 2001 Jul; 412(6843):143-4. PubMed ID: 11449262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aggregation and toxicity of the proteins with polyQ repeats].
    Leźnicki P
    Postepy Biochem; 2005; 51(2):215-22. PubMed ID: 16209359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration.
    Hirabayashi M; Inoue K; Tanaka K; Nakadate K; Ohsawa Y; Kamei Y; Popiel AH; Sinohara A; Iwamatsu A; Kimura Y; Uchiyama Y; Hori S; Kakizuka A
    Cell Death Differ; 2001 Oct; 8(10):977-84. PubMed ID: 11598795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caspase activity sows the seeds of neuronal death.
    Yuan J; Yankner BA
    Nat Cell Biol; 1999 Jun; 1(2):E44-5. PubMed ID: 10559896
    [No Abstract]   [Full Text] [Related]  

  • 5. Glutamine repeats and neurodegeneration.
    Zoghbi HY; Orr HT
    Annu Rev Neurosci; 2000; 23():217-47. PubMed ID: 10845064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death.
    Gong B; Lim MC; Wanderer J; Wyttenbach A; Morton AJ
    Brain Res Bull; 2008 Jan; 75(1):146-57. PubMed ID: 18158109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
    Petersén A; Chase K; Puschban Z; DiFiglia M; Brundin P; Aronin N
    Exp Neurol; 2002 May; 175(1):297-300. PubMed ID: 12009780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions.
    Ross CA; Margolis RL; Becher MW; Wood JD; Engelender S; Cooper JK; Sharp AH
    Prog Brain Res; 1998; 117():397-419. PubMed ID: 9932422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scale-free neurodegeneration: cellular heterogeneity and the stretched exponential kinetics of cell death.
    Clarke G; Lumsden CJ
    J Theor Biol; 2005 Apr; 233(4):515-25. PubMed ID: 15748912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyglutamine disease and neuronal cell death.
    Paulson HL; Bonini NM; Roth KA
    Proc Natl Acad Sci U S A; 2000 Nov; 97(24):12957-8. PubMed ID: 11058149
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic strategies to retard neuronal cell death in neurodegenerative diseases.
    Davis RE
    Curr Opin Investig Drugs; 2001 May; 2(5):654-6. PubMed ID: 11569942
    [No Abstract]   [Full Text] [Related]  

  • 12. Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress.
    Woulfe JM
    Neuropathol Appl Neurobiol; 2007 Feb; 33(1):2-42. PubMed ID: 17239006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trinucleotide repeats and neurodegenerative disease.
    Everett CM; Wood NW
    Brain; 2004 Nov; 127(Pt 11):2385-405. PubMed ID: 15329351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?
    Lashuel HA; Lansbury PT
    Q Rev Biophys; 2006 May; 39(2):167-201. PubMed ID: 16978447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of cell death in polyglutamine expansion diseases.
    Lipinski MM; Yuan J
    Curr Opin Pharmacol; 2004 Feb; 4(1):85-90. PubMed ID: 15018844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New aspects of neuronal cell death: the molecular basis of neurodevelopmental and neurodegenerative disorders].
    Enokido Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):31-5. PubMed ID: 22568124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms underlying polyalanine diseases.
    Messaed C; Rouleau GA
    Neurobiol Dis; 2009 Jun; 34(3):397-405. PubMed ID: 19269323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death?
    Stavrovskaya IG; Kristal BS
    Free Radic Biol Med; 2005 Mar; 38(6):687-97. PubMed ID: 15721979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamine repeats and neurodegenerative diseases: molecular aspects.
    Perutz MF
    Trends Biochem Sci; 1999 Feb; 24(2):58-63. PubMed ID: 10098399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress and neurotoxicity.
    Sayre LM; Perry G; Smith MA
    Chem Res Toxicol; 2008 Jan; 21(1):172-88. PubMed ID: 18052107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.